News | September 28, 2021
Zymo Research donates one million Covid-19 test kits to Mapmygenome
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
The NanoDrop Eight simultaneously evaluates eight samples in 20 seconds or less and the instrument can also measure high-concentration samples of up to 200 absorbance units without dilution
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Barbara Engelhardt moves her computational and statistics lab to Gladstone
The order strengthens the company’s position in the East African market
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
Subscribe To Our Newsletter & Stay Updated
